Comments on: Pharmaceutical industry questions whether maximalist IP is in its own interests https://blog.p2pfoundation.net/pharmaceutical-industry-questions-whether-maximalist-ip-is-in-its-own-interests/2010/02/24 Researching, documenting and promoting peer to peer practices Fri, 26 Feb 2010 13:37:09 +0000 hourly 1 https://wordpress.org/?v=5.5.15 By: Matt Vogelhuber https://blog.p2pfoundation.net/pharmaceutical-industry-questions-whether-maximalist-ip-is-in-its-own-interests/2010/02/24/comment-page-1#comment-422498 Fri, 26 Feb 2010 13:37:09 +0000 http://blog.p2pfoundation.net/?p=7491#comment-422498 Innovation model will not sustain industry for a couple of reasons: development time, no appetite for risk (from investors (re:success rates) to patients (re: unknown side-effect profile) and cost.

Move to branded generics – in all forms – will be the developing model.

]]> By: Sepp Hasslberger https://blog.p2pfoundation.net/pharmaceutical-industry-questions-whether-maximalist-ip-is-in-its-own-interests/2010/02/24/comment-page-1#comment-422424 Wed, 24 Feb 2010 15:29:40 +0000 http://blog.p2pfoundation.net/?p=7491#comment-422424 A good step ahead.

But it is almost painful to watch how long it takes these realizations to sink in and make a dent in what is being done in the real world.

“This is a paradoxical situation where a patent system that was designed to foster innovation is now actually hindering it, Munos said.”

]]>